Abstract:Objective: To study the expression of atrial natriuretic peptide (ANP) in gastric cancer and explore its clinical significance in the development and progression of gastric cancer. Methods: Immunohistochemistry was used to detect the expression of ANP in 40 cases of gastric cancer after resection and 20 cases of normal gastric mucosa. The relationship between the expression of ANP in gastric cancer tissue and the clinicopathological features of the patients' sex, age, degree of differentiation, depth of infiltration, regional lymph node metastasis, tumor stage and tumor typing were analyzed. Results: The positive expression rate of ANP in normal gastric mucosa was 95% (19/20), which was strongly positive. The positive expression rate of ANP in gastric cancer tissues was 90% (54/60), which was weakly expressed. The expression of ANP in normal gastric mucosa was stronger than that in cancer tissue (P<0.05).The expression intensity of ANP in gastric carcinoma was positively correlated with the degree of tumor differentiation (P<0.01, r=0.383), which was negatively correlated with the depth of invasion (P<0.01, r=-0.499), negatively correlated with lymph node metastasis (P<0.01, r=-0.396), and negatively correlated with tumor stage (P<0.01, r= -0.519). The expression intensity of ANP gradually weakened with infiltration depth, lymph node metastasis and stage failure. In addition, the expression intensity of ANP was not correlated with gender, age and tumor type (P>O.05).Multiple factor analysis showed that the degree of differentiation of the tumor was independent of these clinicopathological features affecting the expression of ANP in gastric cancer (P=0.013, 95%CI=1.493 to 27.207, OR=6.256). Conclusion:The expressions of ANP in normal tissues is higher than gastric carcinoma. The ANP expressions of gastic cacinoma is higher in better differentiation degree, but the expressions more decreased in deeper invasion, higher TNM stage and lymph node metastasized. There is no correlation among the groups in gender, age, and classification. So ANP correlates with the occurrence and development of gastric cancer gastric cancer, could be used as biological targeted drug.
[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. Ca A Cancer Journal for Clinicians, 2016, 66(2):115–132. [2] Bagheri N, Azadegan-Dehkordi F, Rahimian G, et al. Altered Th17 Cytokine Expression in Helicobacter pylori Patients with TLR4 (D299G) Polymorphism[J]. Immunological Investigations, 2016, 45(2):161~171. [3] Li Z, Wang JW, Wang WZ, et al. Natriuretic peptide receptor A inhibition suppresses gastric cancer development through reactive oxygen species-mediated G2/M cell cycle arrest and cell death[J]. Free Radical Biology & Medicine, 2016, 99:593~607. [4] Laurent L, Christine R, Marie-Odile J, et al. Gene polymorphisms ofFABP2,ADIPOQ and ANP and risk of hypertriglyceridemia and metabolic syndrome in afro-caribbeans:[J]. Plos One, 2016, 11(9):1~14. [5] Vesely D L. Natriuretic peptides' metabolic targets for treatment of cancer.[J]. Journal of Investigative Medicine the Official Publication of the American Federation for Clinical Research, 2013, 61(5):816~822. [6] Vesely D L. Cardiac hormones for the treatment of cancer.[J]. Endocrine-related cancer, 2013, 20(3):113~125. [7] Nojiri T, Hosoda H, Tokudome T, et al. Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells.[J]. Proc Natl Acad Sci U S A, 2015, 112(13):4086~4091. [8] Choi Y, Ko Y S, Park J, et al. HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer[J]. World Journal of Gastroenterology, 2016, 22(41):9141~9153.